CNMD

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today reported financial results for the second quarter ended June 30, 2026 and updated its financial guidance for the full year ending 2026. Second Quarter 2026 Highlights(1) Sales of $343.5 million increased 0.3% year-over-year as reported and decreased 0.5% on a constant currency(2) basis. Excluding the impact of the Company's previously announced strategic exits of GI product offerings, net sales increased 6.0% on an organic cons.

CNMD's FDA-expanded AirSeal indication adds da Vinci 5 hex cannula compatibility, supporting broader use across Intuitive Surgical's robotic systems.

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that its AirSeal® Robotic Solution is now indicated for use with Intuitive's 8 mm hex cannulas used as part of the Intuitive da Vinci 5 platform (“dV5”). Alongside its existing indication for Intuitive 8 mm round cannulas, the AirSeal Robotic Solution now has an expanded indication for use across Intuitive's portfolio of da Vinci X, da Vinci Xi, and da Vinci 5 robotic systems. Building on the existing indication for I.

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced its participation in the Society of Robotic Surgery (SRS) 2026 Annual Meeting, which is being held July 23-26, 2026 in Fort Lauderdale, FL. During the meeting, Professor Nikhil Vasdev, FRCS (Urol), MCh (Urol), DSc will present data from a prospective randomized controlled clinical trial conducted by Vasdev et al., which investigated differences in the levels of intraoperative and post-operative pain between two abdomi.

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the second quarter 2026 after the market close on Wednesday, July 29, 2026. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed fro.

CNMD is sharpening its focus on AirSeal, Buffalo Filter and BioBrace, betting on higher-growth platforms to drive margin gains and long-term growth.

Conmed (CNMD) reported earnings 30 days ago. What's next for the stock?

CAH's fast-growing Other Growth Businesses posted 34% revenue growth and 52% profit gains, raising their role in long-term earnings.

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced the appointment of Celine Martin and Jeff Mirviss to its Board of Directors (“Board”), effective July 1, 2026. Ms. Martin will serve as a member of the Audit Committee and the Strategy Committee, and Mr. Mirviss will serve as a member of the Compensation Committee and the Corporate Governance and Nominating Committee. In connection with these appointments, CONMED is increasing the size of its Board to include a total.

Investors need to pay close attention to CNMD stock based on the movements in the options market lately.